Transcatheter Mitral Valve Devices Market Snapshot 2024-2028
Overview
Valued at ~$1.3 billion in 2023, the transcatheter mitral valve devices market is projected to
reach ~$3.8 billion by 2028, increasing at a CAGR of 23.3% over the 2023-2028
forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your one-stop-shop for
global medtech market sizing and analysis, procedure volume data, startup company- and deal-tracking, curated
insights, and more.
The transcatheter mitral valve devices market encompasses products employed in the treatment of mitral valve
disease to either repair or replace diseased valves.
Products included within the scope of this analysis include:
Transcatheter mitral valve repair devices
Transcatheter mitral valve replacement devices
This Market Snapshot is intended to provide a high-level overview of the global market for transcatheter mitral
valve devices, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Transcatheter Mitral Valve Devices Market Snapshot Summary
| Snapshot Aspect | Data and Details |
| Base Year for Estimate | 2023 |
| Forecast Period | 2023 - 2028 |
| Market Size in 2023 | $1.3 billion |
| CAGR | 23.2% |
| Projected Market Size in 2028 | $3.8 billion |
Transcatheter Mitral Valve Devices Market Insights
The transcatheter mitral valve devices market is experiencing rapid growth, outpacing the larger, more
established transcatheter
aortic valve market at more than twice the rate. This surge is primarily driven by the prevalence of
mitral valve disease, with 24 million people affected by mitral regurgitation globally, compared to 12.6 million
for calcific aortic valve disease. Suppliers estimate the market opportunity for mitral valve repair and
replacement to be more than $2 billion worldwide, highlighting a significant unmet need for less invasive
treatments—especially for patients who would otherwise face high-risk surgical procedures.
Currently, the only approved devices on the market in the United States for transcatheter mitral valve surgery
are Abbott’s MitraClip™, Edwards’ Sapien 3™, and Edwards’ PASCAL Precision™ TMVr system. Although Abbott and
Edwards dominate the U.S. market, international competition is robust, with numerous startups and established
players like Cardiac Dimensions introducing innovative solutions.
Furthermore, the recent CMS approval for transcatheter mitral valve repair reimbursement in patients with
secondary mitral regurgitation could drastically expand patient access, potentially doubling or tripling the
eligible population for these life-saving procedures.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the transcatheter mitral
valve devices market. This includes estimated market revenue and market share for key players, such as Abbott
and Edwards Lifesciences.
Select Market Events
| Company | Date | Event Type | Event |
|
4C Medical
|
5/2024 | Regulatory | 4C Medical’s AltaValve™ system received FDA Breakthrough Device designation for two therapeutic indications. |
|
Edwards Lifesciences
|
7/2024 | M&A | Edwards Lifesciences announced the acquisition of Innovalve and secured a stake in Affluent Medical. |
Key Companies Covered
4C Medical
Abbott
Cardiac Dimensions
Edwards Lifesciences
Highlife
HVR Cardio
InnovHeart
Medtronic
Microinterventional Devices
Mitralix
MVRx
NeoChord
Open Stent Solution
Opus Medical Therapies
Venus MedTech
